Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,230 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
RAD001, Sorafenib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 21, 2026, 5:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Intracranial Aneurysms
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
6
States / cities
Newark, Delaware • Marietta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Daratumumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
33
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 21, 2026, 5:36 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Severe, Symptomatic, Calcific Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, TAVR Implantation with SAPIEN
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
53
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced May 21, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Interventions
Velocity pAVF System
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Riverside, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma
Interventions
AMG 232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced May 21, 2026, 5:36 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg, zagociguat 30mg, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CEP-18770
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2010 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced May 21, 2026, 5:36 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced May 21, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Abdominal Aortic Aneurysms (AAA)
Interventions
Fenestrated TREO Stent Graft System
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Colorado Springs, Colorado • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Mediastinal Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Kami Maddocks
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced May 21, 2026, 5:36 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
High Risk Pregnancy, Remote Patient Monitoring, Diabetes, Hypertension
Interventions
Fetal ECG monitoring
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Left Atrial Appendage Exclusion
Interventions
AtriCure LAA Exclusion System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Macon, Georgia • Indianapolis, Indiana • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Myeloma
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced May 21, 2026, 5:36 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced May 21, 2026, 5:36 PM EDT
Enrolling by invitation No phase listed Observational
View directory record Official record
Conditions
Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions
Interventions
DETOUR System
Device
Lead sponsor
Endologix
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
Salinas, California • Storrs, Connecticut • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 5:36 PM EDT